Hepatobiliary Cancers : Pathobiology and Translational Advances 2017

Hepatobiliary Cancers : Pathobiology and Translational Advances is organized by Virginia CommonWealth University (VCU) and will be held during Dec 07 - 10, 2017 at Virginia Crossings Hotel & Conference Center, Glen Allen, Virginia, United States of America.

Target Audience:
• Basic and Translational Liver Cancer Researchers
• Hepatopathologists
• Hepatologists
• Hepatic Oncologists
• Residents, Postdoctoral Fellows/Trainees, Ph.D. Graduate Students, and Medical Students Pursuing Careers In Liver Cancer Research
• Members of Patient Advocacy Organizations Promoting Hepatobiliary Cancer Research

This conference is uniquely focused on disseminating cutting edge basic and translational research findings that include sharing significant unpublished work aimed at providing new mechanistic insights into the cellular and molecular pathogenesis of hepatobiliary cancers and advancing present and emerging translational approaches towards identifying and personalizing more effective targeted therapies, as well as devising needed prevention strategies to reverse the unfavorable trends associated with these devastating liver cancers.

Key topic areas that will be covered include hepatobiliary cancer signaling pathways, stemness, microenvironment, microRNA dysregulation, epigenetic modifications and therapeutics, genomic profiling, molecular and immunotherapeutic targeting, changing etiology, and future challenges for therapy and prevention.

Conference Objectives:
• Disseminate new and emerging basic and translational research findings on the cellular and molecular pathogenesis of primary hepatobiliary cancers (hepatocellular carcinomas and intrahepatic cholangiocarcinomas) having implications for therapy and prevention.
• Describe current and emerging research aimed at identifying molecular and immune targets for primary liver cancers, with a focus on personalizing targeted therapies and overcoming therapeutic challenges.
• Define critical risk factors and challenges for the reversing the increasing global incidence of primary liver cancers.
• Provide a collegial and collaborative environment that favors the career development of the next generation of liver cancer researchers.
• Foster productive interactions between translational basic liver cancer researchers, clinical researchers and practitioners, and patient advocates, each dedicated to finding effective new treatments for curing and/or preventing primary liver cancers.